medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-10-36-41medsovet-655Research ArticleКОГНИТИВНЫЕ РАССТРОЙСТВАCOGNITIVE DISRODERSНекоторые аспекты терапии нейродегенеративных деменцийSome aspects of treatment of neurodegenerative dementiasПреображенскаяИ. С.PreobrazhenskayaI. S.noemail@neicon.ruГромоваД. О.GromovaD. O.noemail@neicon.ruКлиника нервных болезней им. А.Я. Кожевникова, Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияClinic for Nervous Diseases named after A.Y. Kozhevnikov, First Moscow State Medical University named after I.M. SechenovRussian Federation2014301220140103641Copyright © Преображенская И.С., Громова Д.О., 20142014Преображенская И.С., Громова Д.О.Preobrazhenskaya I.S., Gromova D.O.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/655

Настоящая статья посвящена лечению нейродегенеративных деменций. Подробно рассмотрены вопросы эффективности ингибиторов ацетилхолинэстеразы, препаратов других фармакотерапевтических групп, а также комбинированной терапии с помощью ингибиторов ацетилхолинэстеразы и холина альфосцерата.

The article is devoted to certain issues in the treatment of neurodegenerative dementias. The effectiveness of acetylcholinesterase inhibitors and drugs from other pharmacological groups, as well as combination therapy with inhibitors of acetylcholinesterase and choline alfoscerate, is highlighted.

деменцияболезнь Альцгеймералечениеингибиторы ацетилхолинэстеразыхолина альфосцератпринципы терапииdementiaAlzheimer's diseasetreatmentacetylcholinesterase inhibitorscholine alfoscerateprinciples of therapyReferencesДамулин И.В. Болезнь Альцгеймера и сосудистая деменция. М., 2002.Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция. М., 2002.Преображенская И.С. Экселон в терапии нейродегенеративных деменций. Неврологический журнал, 2006, 11, 1: 42-47.Преображенская И.С. Экселон в терапии нейродегенеративных деменций. Неврологический журнал, 2006, 11, 1: 42-47.Преображенская И.С. Когнитивные нарушения - выраженность, клинические проявления, диагностика, лечение. ДокторРу. 2013. 5 (83): 2-7.Преображенская И.С. Когнитивные нарушения - выраженность, клинические проявления, диагностика, лечение. ДокторРу. 2013. 5 (83): 2-7.Amenta F, Tayebati SK, Vitali D, Di Tullio MA. Association with the cholinergic precursor choline alphoscerate and the cho-linesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 2006. 127: 173-179.Amenta F, Tayebati SK, Vitali D, Di Tullio MA. Association with the cholinergic precursor choline alphoscerate and the cho-linesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 2006. 127: 173-179.Amenta F et al. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.J.NeurolSci. 2012. 15. 322. 1-2. 96-101.Amenta F et al. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.J.NeurolSci. 2012. 15. 322. 1-2. 96-101.Amenta F et al. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 2006. 127 (2). 173-9.Amenta F et al. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 2006. 127 (2). 173-9.Arendt T, Bruckner MK, Lange M et al. Changes in acetylcholinesterase and, butyrilcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int. 1992. 21. 381-396.Arendt T, Bruckner MK, Lange M et al. Changes in acetylcholinesterase and, butyrilcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int. 1992. 21. 381-396.Brodaty H, Sachdev PS. Drugs for the prevention and treatment of Alzheimer's disease. Med.J. Aust. 1997. 167. 8. 447-449.Brodaty H, Sachdev PS. Drugs for the prevention and treatment of Alzheimer's disease. Med.J. Aust. 1997. 167. 8. 447-449.Bullock R. New drugs for Alzheimer's disease and other dementias. Br.J. Psychiatry. 2002. 180. 135-139.Bullock R. New drugs for Alzheimer's disease and other dementias. Br.J. Psychiatry. 2002. 180. 135-139.Cummings J, Lefevre G, Small G et al. Pharmacokinetic rationale for the rivasigmine patch. 2007. 69. 10-13.Cummings J, Lefevre G, Small G et al. Pharmacokinetic rationale for the rivasigmine patch. 2007. 69. 10-13.Corey-Bloom J., Anand R., Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998. 1. 55-65.Corey-Bloom J., Anand R., Veach J, for the ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998. 1. 55-65.De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. ClinTher. 2003. 25: 1. 178-193.De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. ClinTher. 2003. 25: 1. 178-193.Doggrell SA, Evans S. Treatment of dementia with neurotransmission modulation. Expert OpinInvestig Drugs 2003. 12. 1633-54.Doggrell SA, Evans S. Treatment of dementia with neurotransmission modulation. Expert OpinInvestig Drugs 2003. 12. 1633-54.Doraiswamy M, Anand R, Hartman R. Long-term cognitive effects in Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neurppsychopharmacol Biol Psychiatry. 2002. 26. 705-712.Doraiswamy M, Anand R, Hartman R. Long-term cognitive effects in Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neurppsychopharmacol Biol Psychiatry. 2002. 26. 705-712.Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease. Lancet Neurology 2004, 3: 246-8.Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease. Lancet Neurology 2004, 3: 246-8.Francis LS, Laplanche R. Absorbtion, metabolism and disposition of [14C] SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharmaceutical Research. 1998. 15. 10. 1614-1620.Francis LS, Laplanche R. Absorbtion, metabolism and disposition of [14C] SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharmaceutical Research. 1998. 15. 10. 1614-1620.Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol Neurosurg Psychiat. 1999. 66. 137-147.Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol Neurosurg Psychiat. 1999. 66. 137-147.Galasko D. New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future. Clin. Geriatr. Med. 2001. 17. 2. 393-410.Galasko D. New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future. Clin. Geriatr. Med. 2001. 17. 2. 393-410.Lulu Xie et al. Sleep drives metabolite clearance from the adult brain. Science 2013. 342, 373.Lulu Xie et al. Sleep drives metabolite clearance from the adult brain. Science 2013. 342, 373.Oertel W, Ross JS, Eggert K et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007. 69. 4-9.Oertel W, Ross JS, Eggert K et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007. 69. 4-9.Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. MechAgeingDev 2001. 122. 2041-55.Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. MechAgeingDev 2001. 122. 2041-55.Small BJ, Fratiglioni L, Vitanen M et al. Vellas B et al. Research and practice in Alzheimer's disease. Paris: Serdi Publisher, 2001: 29-34.Small BJ, Fratiglioni L, Vitanen M et al. Vellas B et al. Research and practice in Alzheimer's disease. Paris: Serdi Publisher, 2001: 29-34.Scapicchio PL. Int.J. Neurosci., 2013, 123 (7): 444.Scapicchio PL. Int.J. Neurosci., 2013, 123 (7): 444.Vellas B, Messina J, Hartman R et al. Multi-dimensionality of treatment benefits in Alzheimer's disease: investigating the correlation between activities of daily living and cognition in patients treated with rivastigmine. Research and practice in Alzheimer's disease. 5. Serdi Publishing (Paris), Springer Publishing Company (NY), 2001: 193-204.Vellas B, Messina J, Hartman R et al. Multi-dimensionality of treatment benefits in Alzheimer's disease: investigating the correlation between activities of daily living and cognition in patients treated with rivastigmine. Research and practice in Alzheimer's disease. 5. Serdi Publishing (Paris), Springer Publishing Company (NY), 2001: 193-204.

The authors declare that there are no conflicts of interest present.